Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers
COX-2 is highly expressed in endometrial cancers, suggesting that a selective COX-2 inhibitor could be valuable for treating endometrial cancers that overexpress COX-2. In this study, we investigated the anti-tumor effects of the selective COX-2 inhibitor etodolac on endometrial cancer patients.
Etodolac (400 mg, bid, for 2 weeks) was administered preoperatively to 21 endometrial cancer patients who had provided informed consent. Using pre-treatment biopsies and post-treatment surgical specimens, the expression levels of COX-2, Ki-67, p53, p21, p27, and cyclin D1 were evaluated by immunohistochemistry and the apoptotic index (AI) was determined by TUNEL staining. Preoperative biopsies and surgical specimens from 32 patients with endometrial cancer not treated with etodolac served as controls.
Surgical specimens from COX-2 positive endometrial cancer patients treated with etodolac had significantly reduced expression levels of COX-2, Ki-67, p53, p21, p27, and cyclin D1 as determined by immunohistochemistry, while AI was not affected. These markers were unchanged for COX-2 negative endometrial cancer patients treated with etodolac and the control group.
The selective COX-2 inhibitor etodolac showed anti-proliferative effects by suppressing COX-2 and cell-cycle regulator protein expression in patients with endometrial cancer positive for COX-2 expression. This study demonstrates that a selective COX-2 inhibitor is a potentially beneficial treatment for COX-2 positive endometrial cancers.
KeywordsEndometrial cancer COX-2 COX-2 inhibitor Immunohistochemistry Cell-cycle regulator proteins
Conflict of interest
The authors declare that they have no conflict of interest.
- 15.Wood NJ, Quinton NA, Burdall S, Sheridan E, Duffy SR (2007) Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer-like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression. Int J Gynecol Cancer 17:447–454PubMedCrossRefGoogle Scholar
- 25.Roumie CL, Choma NN, Kaltenbach L, Mitcher EF, Arbogast PG, Griffin MR (2009) Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events- stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf 18:1053–1063PubMedCrossRefGoogle Scholar
- 27.Warner JJ, Weideman RA, Kelly KC, Brilakis ES, Banerjee S, Cunningham F et al (2008) The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a genetic COX-2 selective inhibitor. J Cardiovasc Pharmacol Ther 13:252–260PubMedCrossRefGoogle Scholar
- 28.Yanaoka K, Oka M, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S et al (2010) Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int J Cancer 126:1467–1473PubMedGoogle Scholar
- 36.Shih HC, Shiozawa T, Kato K, Imai T, Miyamoto T, Uchikawa J et al (2003) Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol 34:471–478PubMedCrossRefGoogle Scholar